Skip to main content
NVDA-2.47%AAPL+1.18%GOOGL-0.43%MSFT-0.18%AMZN-0.04%TSM-2.13%SPCX+1.74%AVGO-0.27%META-0.65%TSLA-0.38%SKHY-5.22%MU-3.82%BRK-B-0.01%LLY+0.41%JPM-0.82%AMD-2.64%WMT+0.89%V-0.32%XOM+0.15%ASMLa-3.01%JNJ0.00%INTC-5.77%MA-0.27%0700.HK-1.94%ORCL-2.65%1398.HK+0.79%BAC-0.41%ABBV+0.61%CSCO-0.30%CVX-0.69%COST+0.22%LRCX-4.40%KO+1.35%CAT-1.64%AMAT-2.69%0005.HK-0.78%AP2d-1.98%UNH+0.66%DELL-3.11%HSBA.L-1.42%MS-0.42%PG+0.02%GE-0.24%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.09%HD-1.23%GS-0.92%0939.HK+1.66%NZDJPY-2.69%AUDJPY-2.02%CHFJPY-1.71%USDJPY-1.50%GBPJPY-1.49%EURJPY-1.44%CADJPY-1.41%EURNZD+1.31%NZDCAD-1.30%NZDUSD-1.23%GBPNZD+1.21%NZDCHF-1.02%USDNOK+0.96%USDZAR+0.88%EURNOK+0.85%CHFNOK+0.80%EURZAR+0.78%NOKJPY-0.73%AUDNZD+0.70%GBPZAR+0.66%USDSEK+0.65%AUDCAD-0.64%AUDDKK-0.62%USDMXN+0.60%EURAUD+0.60%EURSEK+0.54%AUDUSD-0.53%AUDSGD-0.52%GBPAUD+0.51%CHFSEK+0.49%USDTHB+0.49%GBPTRY+0.41%USDPLN+0.34%GBPHKD+0.32%AUDCHF-0.32%NZDSGD-0.29%GBPMXN-0.28%CADCHF+0.28%EURCHF+0.26%EURPLN+0.23%AUDNOK+0.23%USDCHF+0.22%USDSGD+0.21%GBPCHF+0.20%USDILS+0.16%EURHKD-0.13%PLNJPY-0.11%USDDKK+0.11%USDTRY+0.11%GBPCAD-0.10%EURSGD+0.10%NZDMXN+0.08%EURGBP+0.08%USDCAD-0.07%EURUSD+0.06%USDCNH+0.05%CHFSGD+0.04%USDCOP-0.04%EURCNH-0.04%GBPSGD-0.03%SGDJPY+0.03%EURCAD-0.02%EURCZK0.00%USDHKD0.00%EURDKK0.00%GBPUSD0.00%XPTUSD-4.55%HG1-4.30%XAGUSD-4.25%GAGUSD-4.25%UKOIL+2.75%USOIL+2.44%COFFEE-1.86%XAUUSD-0.88%GAUUSD-0.88%W1-0.85%COCOA-0.70%C1-0.42%BTCUSD-1.50%ETHUSD-1.40%USDTUSD-0.05%XRPUSD-2.26%SOLUSD-1.91%TRXUSDT-0.06%ZECUSDT-6.27%DOGEUSD-2.82%XMRUSDT-1.63%LINKUSD-1.27%XLMUSD-1.99%BCHUSDT-9.63%LTCUSD-1.54%UNIUSD-3.92%HBARUSDT-1.68%TONUSD+24.88%SUIUSD-3.17%TAOUSDT-4.43%AAVEUSD-2.97%DOTUSDT-3.07%ICPUSDT-0.65%ONDOUSDT-2.84%WLDUSDT-2.67%ATOMUSDT-3.03%ARBUSDT+1.71%JUPUSDT-2.96%INJUSDT-3.59%STXUSDT-3.43%FETUSDT-2.98%TIAUSDT-1.13%PYTHUSDT-1.00%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-4.89%GRTUSDT-3.13%OPUSDT-3.00%IOTAUSDT-3.54%POLUSDT-6.59%AXSUSDT-2.47%FARTCOINUSDT-2.79%EOSUSDT-1.18%DYDXUSDT-0.88%ORDIUSDT-0.61%GALAUSDT-4.21%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.47%AAPL+1.18%GOOGL-0.43%MSFT-0.18%AMZN-0.04%TSM-2.13%SPCX+1.74%AVGO-0.27%META-0.65%TSLA-0.38%SKHY-5.22%MU-3.82%BRK-B-0.01%LLY+0.41%JPM-0.82%AMD-2.64%WMT+0.89%V-0.32%XOM+0.15%ASMLa-3.01%JNJ0.00%INTC-5.77%MA-0.27%0700.HK-1.94%ORCL-2.65%1398.HK+0.79%BAC-0.41%ABBV+0.61%CSCO-0.30%CVX-0.69%COST+0.22%LRCX-4.40%KO+1.35%CAT-1.64%AMAT-2.69%0005.HK-0.78%AP2d-1.98%UNH+0.66%DELL-3.11%HSBA.L-1.42%MS-0.42%PG+0.02%GE-0.24%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.09%HD-1.23%GS-0.92%0939.HK+1.66%NZDJPY-2.69%AUDJPY-2.02%CHFJPY-1.71%USDJPY-1.50%GBPJPY-1.49%EURJPY-1.44%CADJPY-1.41%EURNZD+1.31%NZDCAD-1.30%NZDUSD-1.23%GBPNZD+1.21%NZDCHF-1.02%USDNOK+0.96%USDZAR+0.88%EURNOK+0.85%CHFNOK+0.80%EURZAR+0.78%NOKJPY-0.73%AUDNZD+0.70%GBPZAR+0.66%USDSEK+0.65%AUDCAD-0.64%AUDDKK-0.62%USDMXN+0.60%EURAUD+0.60%EURSEK+0.54%AUDUSD-0.53%AUDSGD-0.52%GBPAUD+0.51%CHFSEK+0.49%USDTHB+0.49%GBPTRY+0.41%USDPLN+0.34%GBPHKD+0.32%AUDCHF-0.32%NZDSGD-0.29%GBPMXN-0.28%CADCHF+0.28%EURCHF+0.26%EURPLN+0.23%AUDNOK+0.23%USDCHF+0.22%USDSGD+0.21%GBPCHF+0.20%USDILS+0.16%EURHKD-0.13%PLNJPY-0.11%USDDKK+0.11%USDTRY+0.11%GBPCAD-0.10%EURSGD+0.10%NZDMXN+0.08%EURGBP+0.08%USDCAD-0.07%EURUSD+0.06%USDCNH+0.05%CHFSGD+0.04%USDCOP-0.04%EURCNH-0.04%GBPSGD-0.03%SGDJPY+0.03%EURCAD-0.02%EURCZK0.00%USDHKD0.00%EURDKK0.00%GBPUSD0.00%XPTUSD-4.55%HG1-4.30%XAGUSD-4.25%GAGUSD-4.25%UKOIL+2.75%USOIL+2.44%COFFEE-1.86%XAUUSD-0.88%GAUUSD-0.88%W1-0.85%COCOA-0.70%C1-0.42%BTCUSD-1.50%ETHUSD-1.40%USDTUSD-0.05%XRPUSD-2.26%SOLUSD-1.91%TRXUSDT-0.06%ZECUSDT-6.27%DOGEUSD-2.82%XMRUSDT-1.63%LINKUSD-1.27%XLMUSD-1.99%BCHUSDT-9.63%LTCUSD-1.54%UNIUSD-3.92%HBARUSDT-1.68%TONUSD+24.88%SUIUSD-3.17%TAOUSDT-4.43%AAVEUSD-2.97%DOTUSDT-3.07%ICPUSDT-0.65%ONDOUSDT-2.84%WLDUSDT-2.67%ATOMUSDT-3.03%ARBUSDT+1.71%JUPUSDT-2.96%INJUSDT-3.59%STXUSDT-3.43%FETUSDT-2.98%TIAUSDT-1.13%PYTHUSDT-1.00%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-4.89%GRTUSDT-3.13%OPUSDT-3.00%IOTAUSDT-3.54%POLUSDT-6.59%AXSUSDT-2.47%FARTCOINUSDT-2.79%EOSUSDT-1.18%DYDXUSDT-0.88%ORDIUSDT-0.61%GALAUSDT-4.21%NOTUSDT-2.97%RONINUSDT-2.64%
AB

ArriVent BioPharma, Inc. (AVBP)

NASDAQ • Healthcare

$29.79
-$0.49 (-1.6%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$30.02
Previous Close$29.79
Day Range$29.4 - $30.26
Avg. Volume (3M)419.3K
Market Cap$1.3B
52 Week Range
$17$35.83
Next EarningsIn 67 daysNov 16, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$163.7M
EPS (TTM)
-$3.68
ROA (TTM)
-41.48%
Current Ratio
14.16

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+10.3%Q1 2026-$0.78
-9.1%Q2 2026-$0.96
-6.3%Q3 2026-$1.05
Next

Nov 16

in 67 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -6.3%

ArriVent BioPharma trailed consensus on EPS in the second fiscal quarter of 2026, reported August 12, 2026, with preliminary results showing EPS of -$1.05 versus the -$0.99 estimate (difference -$0.06) and a GAAP net loss that widened 58.9% year over year to about -$49.9 million (from roughly -$31.4 million a year ago). The per-share loss also widened 16.7% from -$0.90 a year ago, alongside GAAP operating income of about -$52.7 million as the company continued advancing its oncology pipeline, including firmonertinib in EGFR-mutant non-small cell lung cancer. Cash use remained elevated, with operating cash flow of roughly -$39.6 million for the quarter. For the next period, consensus calls for EPS of -$1.07 on revenue of $800,000.00.

View full earnings history

About ArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. is a NASDAQ-listed healthcare company in biotechnology that identifies, develops, and aims to commercialize medicines for cancers with unmet medical needs. In qualitative terms, it is an early-stage oncology biopharma built around a small pipeline of targeted and antibody-based drug candidates.

Name
ArriVent BioPharma, Inc.
CEO
Zhengbin Yao
Website
arrivent.com
Industry
Healthcare
Year Founded
2021
Employees
77

Today's Snapshot

AI-generated

Yesterday AVBP fell 1.6% to 29.79.

Trading Volume

Below 10d avg (388.7K)

280.1K

vs S&P 500 Today

Underperforming Market

-1.14%

Updated: September 10, 2026 at 12:10 UTC

Technical Indicators

2 Buy3 Neutral3 Sell
AVBP appears technically neutral with low trend strength and mixed momentum. ADX is low, reflecting a lack of clear directional conviction, while short-term momentum leans slightly negative even as RSI and other oscillators sit near neutral. The stock trades below several short- to mid-term moving averages yet remains above longer-term averages, and on-balance volume tilts toward selling pressure. Volatility is moderate by ATR and the classic pivot level is marginally above the current price, highlighting nearby resistance. Technical takeaway: Neutral.
All signals
  • EMA (5 indicators)$26.70 - $30.53
    Sell
  • RSI (14)45.63
    Neutral
  • Stochastic %K (14, 3, 3)61.56
    Neutral
  • MACD Level (12, 26)-0.10
    Neutral

Peers & Related Assets

ERASErasca, Inc.
$15.7-3.6%
IOVAIovance Biotherapeutics, Inc.
$8.43-3.1%
MBXMBX Biosciences, Inc. Common Stock
$62.91-0.1%
MGTXMeiraGTx Holdings plc
$13.26-2.0%
REPLReplimune Group, Inc.
$14.45-2.2%
ARVNArvinas, Inc.
$8.76-3.5%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.